增强深部大脑准的焦点和强度:在帕金森病多通道时干扰刺激的形研究中,提高了帕金森病的焦点和强度
Bangyu Wang1, Ziqian Zhao1, Rui-Ning Guo1
1Key Laboratory of Exercise and Health Sciences (Ministry of Education), Shanghai Frontiers Science Research Base of Exercise and Metabolic Health, and School of Exercise and Health, Shanghai University of Sport, 399 Changhai Road, Shanghai 200438, China.
Neuroscience
|July 20, 2025
概括
一种新的多通道时间干扰刺激 (M-TIS) 方法非侵入性地针对帕金森病 (PD) 治疗的大脑. 与其他方法相比,M-TIS在内球 (GPi) 中显示出更高的精度和强度.
科学领域:
- 神经科学是一个神经科学.
- 生物医学工程 生物医学工程
- 医学物理 医学物理
背景情况:
- 帕金森病 (PD) 的治疗往往涉及侵袭性深度大脑刺激,准内球体 (GPi).
- 非侵入性神经调节技术旨在改善PD治疗的可访问性和降低风险.
- 目前的非侵入性方法,如跨交替电流刺激 (tACS) 和时间干扰刺激 (TIS),在焦点和强度上有局限性.
研究的目的:
- 引入和评估一种新的多道时间干扰刺激 (M-TIS) 范式.
- 评估M-TIS在非侵入性向GPi治疗PD治疗中的有效性.
- 将M-TIS的刺激强度和焦点与传统的tACS,多通道tACS (M-tACS) 和传统的TIS进行比较.
主要方法:
- 开发一种新的M-TIS范式.
- 利用来自MRI数据的现实的人头模型.
- 采用有限元建模来模拟和分析电场分布和强度.
主要成果:
- 与tACS (0.27V/m),M-tACS (0.38V/m) 和TIS (0.48V/m) 相比,M-TIS在GPi中实现了显著更高的平均电场强度 (0.58V/m).
- M-TIS显示了增强的调制幅度和空间梯度,表明刺激效率和精度有所提高.
- 模拟证实M-TIS在目标GPi区域内具有优越的焦点.
结论:
- M-TIS提出了一个有前途的非侵入性神经调节策略,用于针对GPi.
- 增强的强度和M-TIS的焦点提供了一个潜在的替代方案,以深度大脑刺激的PD治疗.
- 这些发现支持进一步临床翻译和优化M-TIS协议,以改善PD患者的治疗结果.
相关概念视频
Parkinson's Disease: Treatment
381
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
381
Parkinson's Disease: Overview
713
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
713


